

18. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. *J Clin Endocrinol Metab.* 2002; 87(8): 3656.
19. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. *Goodwin JS SO N Engl J Med.* 2005; 352(2): 154.
20. Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. *J Clin Densitom.* 2013; 16(4): 472–481.
21. Kanis JA, Oden A, Johansson H et al. FRAX((R)) and its applications to clinical practice. *Bone.* 2009; 44: 734–743.
22. Stepan JJ, Vaculik J, Pavelka K et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. *Calcif Tissue Int.* 2012; 90(5): 365–372.
23. Dent E, Morley JE, Cruz-Jentoft AJ et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. *J Nutr Health Aging.* 2018; 22(10): 1148–1161.
24. Harvey NC, Biver E, Kaufman JM et al. The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). *Osteoporos Int.* 2017; 28: 447–462.
25. Rizzoli R. Dairy products, yogurts, and bone health. *Am J Clin Nutr* 2014; 99(5 Suppl): 1256s–1262s.
26. Rizzoli R, Stevenson JC, Bauer JM et al. ESCEO Task Force. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Maturitas.* 2014; 79: 122–132.
27. Rizzoli R. Nutritional influence on bone: role of gut microbiota. *Aging ClinExp Res.* 2019; 31(6): 743–751.
28. Giustina A, Adler RA, Binkley N et al. Consensus statement from 2<sup>nd</sup> international conference on controversies in vitamin D. *Rev Endocr Metab Disord* 2020; 21: 89–116.
29. Rochira V, Antonio L & Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. *Andrology* 2018; 6: 272–285.
30. Kaufman JM, Reginster JY, Boonen S et al. Treatment of osteoporosis in men. *Bone.* 2013; 53: 134–144.
31. Sawka AM, Papaioannou A, Adachi JD et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. *BMC Musculoskelet Disord.* 2005; 6: 39.
32. Boonen S, Lorenc RS, Wenderoth D et al. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. *Bone.* 2012; 51: 383–388.
33. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. *Rheumatol Int.* 2009; 29: 311–315.
34. Sato Y, Iwamoto J, Kanoko T et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. *Arch Int Med.* 2005; 165: 1743–1748.
35. Lyles KW, Colón-Emeric CS, Magaziner JS, HORIZON Recurrent Fracture Trial, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med.* 2007; 357: 1799–1809.
36. Boonen S, Orwoll E, Magaziner J, HORIZON Recurrent Fracture Trial, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. *J Am Geriatr Soc.* 2011; 59: 2084–2090.
37. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med.* 2012; 367: 1714–1723.
38. Khan AA, Morrison A, Kendler DL et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. *J Clin Densitom.* 2017; 20(1): 8–24.
39. Genant HK, Libanati C, Engelke K et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. *Bone.* 2013; 56: 482–488.
40. Smith MR, Egerdie B, Hernández Toriz N. Denosumab HALT Prostate Cancer Study Group, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med.* 2009; 361: 745–755.
41. Orwoll E, Teglbjærg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab.* 2012; 97: 3161–3169.
42. Langdahl BL, Teglbjærg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. *J Clin Endocrinol Metab.* 2015; 100: 1335–1342.
43. Tourdi E, Langdahl B, Cohen-Solal M et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. *Bone* 2017; 105: 11–17.
44. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide (human parathyroid hormone (1–34)) therapy on bone density in men with osteoporosis. *J Bone Miner Res.* 2003; 18: 9–17.
45. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum.* 2009; 60: 3346–3355.
46. Díez-Pérez A, Marin F, Eriksen EF et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. *Bone.* 2019; 120: 1–8.

## KNIŽNÍ NOVINKA



### ŽÍLY, ŽILKY A VARIXY

Peter Baláz

Onemocnění žil patří k nejrozšířenějším poruchám, s nimiž se v průběhu života setkává většina z nás. Významným aspektem přitom je fakt, že kromě zdravotních komplikací a rizik jde pro mnohé z nás rovněž o problém estetický.

Knižní publikace určená široké veřejnosti nenáročným a srozumitelným způsobem přibližuje vznik žilního onemocnění, vysvětluje rozdíl jednotlivých forem a popisuje možnosti prevence a léčby. Pomocí ilustrací, fotografií a jednoduchého pochopitelného výkladu připraví čtenáře na to, co by měl očekávat v lékařské ordinaci, názorně vysvětlí rozdíly v jednotlivých léčebných metodách a hlavně ulehčí rozhodnutí o podstoupení zákroku, které mnozí z nás dlouho odkládají. Kniha obsahuje přehled všech dostupných metod léčby, od sklerotizace, laseru až po operační metody pokročilých forem žilního onemocnění.

Maxdorf 2021, 92 str., barevné ilustrace, Formát: 130 x 200 mm, brožovaná, ISBN: 978-80-7345-692-4, Cena: 195 Kč